Aclaris Therapeutics, Inc. ACRS

Company Overview

Aclaris Therapeutics, Inc. is a U.S.-based biopharmaceutical company focused on developing immuno-inflammatory therapies and precision medicine approaches in dermatology and related immunologic diseases. The company operates primarily within the biotechnology and specialty pharmaceutical industries, with an emphasis on small-molecule drug development targeting kinase signaling pathways. Historically, Aclaris commercialized dermatology products, but in recent years it has shifted toward a development-stage biotechnology model centered on immunology and inflammation research.

The company’s principal business activities include advancing investigational therapeutics targeting conditions such as atopic dermatitis, alopecia areata, vitiligo, and other immune-mediated disorders. Aclaris has concentrated much of its research on kinase inhibition technologies, including Janus kinase (JAK) and MK2 pathway modulation. Its strategic positioning is based on proprietary discovery capabilities, internal drug-development expertise, and a pipeline of selective kinase inhibitors intended to address diseases with unmet medical need. Aclaris was founded in 2012 and evolved through acquisitions, licensing arrangements, and internal research programs before narrowing its focus toward clinical-stage immuno-inflammatory therapeutics.